Lurasidone

Overview

Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.

Indication

Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old. It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.

Associated Conditions

Depression, Bipolar
Schizophrenia

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Lurasidone Non-Interventional Study in Schizophrenia Patients	2024/07/30	NCT06527885	N/A	Completed	Aziende Chimiche Riunite Angelini Francesco S.p.A
Sequential Multiple Assignment Randomized Trial for Bipolar Depression	2024/05/30	NCT06433635	Phase 4	Recruiting	Massachusetts General Hospital
Sleep Quality, Cognitive Performance, and Computerized Cognitive Training	2024/03/25	NCT06328140	N/A	Withdrawn	George West Mental Health Foundation d/b/a Skyland Trail
Chinese Longitudinal and Systematic Study of Bioplar Disorder	2022/07/29	NCT05480150	Not Applicable	Recruiting	First Affiliated Hospital of Zhejiang University
Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)	2022/04/28	NCT05351736	Phase 4	Recruiting	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine	2022/01/28	NCT05213143	Phase 4	Terminated	Sumitomo Pharma (Suzhou) Co., Ltd.
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia	2021/08/18	NCT05011669	Phase 4	Completed	Sumitomo Pharma (Suzhou) Co., Ltd.
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients	2020/06/16	NCT04432688	N/A	Completed	Sumitomo Pharma (Suzhou) Co., Ltd.
A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression	2020/05/12	NCT04383691	Phase 3	Terminated	Sumitomo Pharma (Suzhou) Co., Ltd.
Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"	2020/03/18	NCT04312503	N/A	Completed	Aziende Chimiche Riunite Angelini Francesco S.p.A

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
lurasidone hydrochloride	Ascend Laboratories, LLC	67877-638	ORAL	20 mg in 1 1	1/5/2023
Lurasidone hydrochloride	Zydus Lifesciences Limited	70771-1737	ORAL	80 mg in 1 1	9/27/2023
Lurasidone Hydrochloride	Alembic Pharmaceuticals Inc.	62332-497	ORAL	80 mg in 1 1	1/25/2023
Latuda	Sumitomo Pharma America, Inc.	63402-304	ORAL	40 mg in 1 1	7/21/2023
Lurasidone Hydrochloride	Cipla USA, Inc.	69097-939	ORAL	60 mg in 1 1	1/19/2023
Lurasidone hydrochloride	Dr. Reddys Laboratories Inc	43598-353	ORAL	60 mg in 1 1	12/6/2022
Lurasidone Hydrochloride	Alembic Pharmaceuticals Inc.	62332-496	ORAL	60 mg in 1 1	1/25/2023
lurasidone hydrochloride	Macleods Pharmaceuticals Limited	33342-419	ORAL	20 mg in 1 1	6/26/2023
Lurasidone Hydrochloride	Torrent Pharmaceuticals Limited	13668-464	ORAL	20 mg in 1 1	3/20/2023
Lurasidone Hydrochloride	Alembic Pharmaceuticals Limited	46708-495	ORAL	40 mg in 1 1	1/25/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
Latuda	Aziende Chimiche Riunite Angelini Francesco S.p.A.,Viale Amelia 70,00181,Roma,Italy	Authorised	3/21/2014
Latuda	Aziende Chimiche Riunite Angelini Francesco S.p.A.,Viale Amelia 70,00181,Roma,Italy	Authorised	3/21/2014

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
LATUDA TABLET 20MG	Bushu Pharmaceuticals Ltd (Kawagoe Factory), OLIC (Thailand) Ltd (Primary and Secondary Packager)	SIN16346P	TABLET, FILM COATED	20mg	10/12/2021
LATUDA TABLET 40MG	Bushu Pharmaceuticals Ltd (Kawagoe Factory), OLIC (Thailand) Ltd (Primary and Secondary Packager)	SIN15088P	TABLET, COATED	40mg	9/14/2016
LATUDA TABLET 80MG	Bushu Pharmaceuticals Ltd (Kawagoe Factory), OLIC (Thailand) Ltd (Primary and Secondary Packager)	SIN15089P	TABLET, COATED	80 mg	9/14/2016

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
LATUDA TABLETS 80MG	N/A	DKSH Hong Kong Limited	N/A	N/A	11/4/2016

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
PHARMACOR LURASIDONE lurasidone hydrochloride 20 mg film-coated tablet bottle	324023	Pharmacor Pty Ltd	Medicine	A	10/16/2020
APO-LURASIDONE lurasidone hydrochloride 40 mg film-coated tablet blister pack	321646	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	6/24/2020
APO-LURASIDONE lurasidone hydrochloride 80 mg film-coated tablet blister pack	321647	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	6/24/2020
LATUDA lurasidone hydrochloride 20 mg film-coated tablet blister pack	206654	Servier Laboratories (Aust) Pty Ltd	Medicine	A	4/16/2014
PHARMACOR LURASIDONE lurasidone hydrochloride 40 mg film-coated tablet blister pack	324021	Pharmacor Pty Ltd	Medicine	A	10/16/2020
LURASIDONE LUPIN lurasidone hydrochloride 80 mg film-coated tablet blister pack	317202	Lupin Australia Pty Limited	Medicine	A	5/7/2020
MSN-LURASIDONE lurasidone hydrochloride 80 mg tablet blister pack	317303	Accelagen Pty Ltd	Medicine	A	3/17/2020
LURASIDONE SUN lurasidone hydrochloride 40 mg film-coated tablet blister pack	330268	Sun Pharma ANZ Pty Ltd	Medicine	A	11/12/2020
LURACOR lurasidone hydrochloride 20 mg film-coated tablet bottle	324031	Pharmacor Pty Ltd	Medicine	A	10/16/2020
LURASIDONE-WGR lurasidone hydrochloride 80 mg film-coated tablet blister pack	437290	GM Pharma International Pty Ltd	Medicine	A	4/17/2024

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
LATUDA	sumitomo pharma canada, inc.	02413361	Tablet - Oral	60 MG	3/14/2014
PMS-LURASIDONE	Pharmascience Inc	02505916	Tablet - Oral	120 MG	5/2/2022
LATUDA	sumitomo pharma canada, inc.	02387751	Tablet - Oral	40 MG	9/6/2012
LURASIDONE	sanis health inc	02548615	Tablet - Oral	80 MG	12/17/2024
JAMP LURASIDONE	Jamp Pharma Corporation	02516470	Tablet - Oral	120 MG	9/2/2022
SANDOZ LURASIDONE	Sandoz Canada, Inc.	02521075	Tablet - Oral	20 MG	4/7/2022
SANDOZ LURASIDONE	Sandoz Canada, Inc.	02521091	Tablet - Oral	40 MG	4/7/2022
NRA-LURASIDONE	nora pharma inc	02522349	Tablet - Oral	80 MG	9/23/2024
LURASIDONE	sanis health inc	02548623	Tablet - Oral	120 MG	N/A
SANDOZ LURASIDONE	Sandoz Canada, Inc.	02521105	Tablet - Oral	60 MG	4/7/2022

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in Canadian Market

4 months ago

Sunshine Biopharma's Canadian subsidiary, Nora Pharma Inc., has introduced generic Lurasidone for schizophrenia and bipolar depression treatment, entering the global $1.2 billion market that is projected to reach $2.5 billion by 2033.

Transneural Therapeutics Unveils Novel Non-Hallucinogenic Neuroplastogens for Neuropsychiatric Disorders

4 months ago

Transneural Therapeutics has emerged from stealth mode with a preclinical pipeline of non-hallucinogenic neuroplastogens designed to treat neuropsychiatric and neurodegenerative diseases.

Bipolar Depression Market Set to Grow Through 2034 with New Therapies in Pipeline

6 months ago

• The global bipolar depression market is projected to experience significant growth through 2034, driven by increasing prevalence, with the United States accounting for approximately 85% of the market share across major regions. • Several pharmaceutical companies including NeuroRx, COMPASS Pathways, and Intra-Cellular Therapies are advancing novel treatments, with Johnson & Johnson's recent $14.6 billion acquisition of Intra-Cellular Therapies highlighting industry confidence in the sector. • Among current therapies, CAPLYTA (lumateperone) is expected to achieve the highest market share by 2034, while emerging treatments like NRX-100/101 and COMP 360 (psilocybin) show promise for addressing unmet needs in bipolar depression management.

NRx Pharmaceuticals Submits NDA Section to FDA for NRX-100 (Ketamine) in Suicidal Depression

8 months ago

NRx Pharmaceuticals has filed the initial section of its New Drug Application (NDA) to the FDA for NRX-100 (ketamine) to treat suicidal depression.

NRx Pharmaceuticals Advances NRX-100 and NRX-101 for Suicidal Depression, Eyes 2024 NDA Filings

9 months ago

NRx Pharmaceuticals is on track to file NDAs for NRX-100 (IV Ketamine) and NRX-101 (Oral D-Cycloserine/Lurasidone) by year-end 2024 for treating suicidal ideation and bipolar depression.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access